rsid,chrom,start,ref,alts,genotype,weight,state,conclusion,priority,gene,phenotype,category
rs1801133,1,11796321,G,A,A/A,-1.2,risk,"MTHFR C677T TT homozygous — enzyme retains only ~30% activity at body temperature. Significantly elevated homocysteine, especially with low folate. Associated with neural tube defect risk, cardiovascular disease, and impaired methylation. Strongly consider methylfolate (5-MTHF) and riboflavin (B2) supplementation.",high,MTHFR,Reduced methylation — elevated homocysteine,methylation
rs1801133,1,11796321,G,A,A/G,-0.5,risk,"MTHFR C677T CT heterozygous — ~65% enzyme activity. Mildly elevated homocysteine risk, primarily when folate intake is low. Methylfolate supplementation beneficial; standard folic acid is less efficiently converted.",medium,MTHFR,Mildly reduced methylation capacity,methylation
rs1801133,1,11796321,G,A,G/G,0.0,neutral,"MTHFR C677T wild-type CC — normal enzyme activity and thermostability. Standard folate metabolism.",low,MTHFR,Normal methylation,methylation
rs1801131,1,11794419,T,G,G/G,-0.7,risk,"MTHFR A1298C CC homozygous — ~60% residual enzyme activity. Reduced 5-methylTHF production. When combined with 677CT (compound heterozygote), clinical profile resembles 677TT. Consider methylfolate supplementation.",medium,MTHFR,Reduced methylation — MTHFR A1298C,methylation
rs1801131,1,11794419,T,G,G/T,-0.3,risk,"MTHFR A1298C AC heterozygous — mildly reduced activity. Clinical significance primarily in combination with C677T variants.",low,MTHFR,Mildly reduced methylation,methylation
rs1801131,1,11794419,T,G,T/T,0.0,neutral,"MTHFR A1298C wild-type AA — normal enzyme function at this locus.",low,MTHFR,Normal methylation,methylation
rs1805087,1,236885200,A,G,G/G,-0.7,risk,"MTR A2756G GG homozygous — reduced methionine synthase activity. Impaired homocysteine remethylation. Associated with increased neural tube defect risk. Adequate B12 status critical.",medium,MTR,Reduced methionine synthesis,methylation
rs1805087,1,236885200,A,G,A/G,-0.3,risk,"MTR A2756G AG heterozygous — mildly reduced methionine synthase activity. Ensure adequate B12 intake to support enzyme function.",low,MTR,Mildly reduced methionine synthesis,methylation
rs1805087,1,236885200,A,G,A/A,0.0,neutral,"MTR A2756G wild-type AA — normal methionine synthase activity.",low,MTR,Normal methionine synthesis,methylation
rs1801394,5,7870860,A,G,G/G,-0.6,risk,"MTRR A66G GG homozygous — reduced methionine synthase reductase activity. Impairs regeneration of active MTR. Combined with MTHFR/MTR variants, compounds methylation deficiency. B12 and methylfolate supplementation recommended.",medium,MTRR,Impaired MTR regeneration,methylation
rs1801394,5,7870860,A,G,A/G,-0.3,risk,"MTRR A66G AG heterozygous — mildly reduced reductase activity. Clinically significant mainly in combination with other methylation pathway variants.",low,MTRR,Mildly impaired MTR regeneration,methylation
rs1801394,5,7870860,A,G,A/A,0.0,neutral,"MTRR A66G wild-type AA — normal methionine synthase reductase function.",low,MTRR,Normal MTR regeneration,methylation
rs4680,22,19963748,G,A,A/A,-0.3,risk,"COMT Val158Met Met/Met — slow COMT activity. Higher dopamine and estrogen levels in prefrontal cortex. Better working memory and cognitive flexibility, but increased anxiety sensitivity and stress reactivity. Higher SAM consumption for methylation.",medium,COMT,Slow catecholamine metabolism — anxiety risk,comt
rs4680,22,19963748,G,A,A/G,0.0,neutral,"COMT Val158Met Val/Met — intermediate COMT activity. Balanced profile between cognitive performance and stress resilience.",low,COMT,Intermediate catecholamine metabolism,comt
rs4680,22,19963748,G,A,G/G,0.0,neutral,"COMT Val158Met Val/Val — fast COMT activity. Lower prefrontal dopamine, higher stress resilience (warrior phenotype). Slightly lower working memory performance under no-stress conditions.",low,COMT,Fast catecholamine metabolism,comt
rs61330082,7,106286541,C,T,T/T,-0.8,risk,"NAMPT promoter TT — reduced NAMPT/visfatin expression. Lower NAD+ salvage pathway capacity. May accelerate age-related NAD+ decline. NMN or NR supplementation may compensate.",medium,NAMPT,Reduced NAD+ salvage capacity,nad_pathway
rs61330082,7,106286541,C,T,C/T,-0.4,risk,"NAMPT promoter CT — moderately reduced NAMPT expression. Mild impact on NAD+ salvage. Consider NMN/NR supplementation with aging.",low,NAMPT,Mildly reduced NAD+ salvage,nad_pathway
rs61330082,7,106286541,C,T,C/C,0.0,neutral,"NAMPT wild-type CC — normal NAMPT expression and NAD+ salvage capacity.",low,NAMPT,Normal NAD+ salvage,nad_pathway
rs7895833,10,67884669,A,G,G/G,-0.8,risk,"SIRT1 promoter GG — reduced SIRT1 expression. Associated with increased visceral adiposity, insulin resistance, and elevated cardiovascular risk. SIRT1 is a master regulator of aging via NAD+-dependent deacetylation. Caloric restriction and NAD+ precursors may partially compensate.",medium,SIRT1,Reduced SIRT1 — accelerated aging markers,nad_pathway
rs7895833,10,67884669,A,G,A/G,-0.3,risk,"SIRT1 promoter AG — moderately reduced SIRT1 expression. Intermediate metabolic risk profile.",low,SIRT1,Moderately reduced SIRT1 expression,nad_pathway
rs7895833,10,67884669,A,G,A/A,0.3,protective,"SIRT1 promoter AA — normal/enhanced SIRT1 expression. Associated with lower visceral fat and better insulin sensitivity. Favorable aging profile.",low,SIRT1,Normal SIRT1 expression — favorable aging,nad_pathway
rs3741534,11,71165382,C,T,T/T,-0.6,risk,"NADSYN1 variant TT — reduced NAD synthetase efficiency. Lower circulating NAD+ levels observed in metabolomics GWAS. May compound with NAMPT variants for overall NAD+ deficit.",medium,NADSYN1,Reduced de novo NAD+ synthesis,nad_pathway
rs3741534,11,71165382,C,T,C/T,-0.3,risk,"NADSYN1 variant CT — mildly reduced NAD synthetase efficiency. Minor impact on circulating NAD+ levels.",low,NADSYN1,Mildly reduced NAD+ synthesis,nad_pathway
rs3741534,11,71165382,C,T,C/C,0.0,neutral,"NADSYN1 wild-type CC — normal NAD synthetase activity and de novo NAD+ synthesis.",low,NADSYN1,Normal NAD+ synthesis,nad_pathway
